Argus Starts Regeneron Pharma (REGN) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $973.36 +1.26%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Argus initiated coverage on Regeneron Pharma (NASDAQ: REGN) with a Buy rating and a price target of $375.00.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $305.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron shares hit 52-week high on earnings beat
- Argus Downgrades Teladoc (TDOC) to Sell
- Stephens Starts Dropbox (DBX) at Equal Weight, 'Show Us Growth'
Create E-mail Alert Related Categories
New CoverageRelated Entities
ArgusSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
